electroCore Inc.

NASDAQ: ECORHealthcare / Medical Instruments & Supplies / USA
1.6900.00Vol 90 9231Y Perf -87.73%
Aug 20th, 2019 16:00
BID1.54 ASK1.70
Open1.74 Previous Close1.69
Pre-Market- After-Trading-
 - -%  - -%
Target Price
10.00 
Analyst Rating
Moderate Buy 2.33
Potencial %
491.72 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
100/-20/-20 
Value Ranking
 —    -
Insiders Value % 3/6/12M
100/-79/-67 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
100/-45/-52 
Income Ranking
 —    -
Market Cap (mil)50 
Earnings Rating
Neutral
Price Range Ratio 52wk %
2.74 
Earnings Date
13th Aug 2019

Today's Price Range

1.651.76

52wk Range

1.2317.99

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
21.58%
1 Month
35.20%
3 Months
-46.01%
6 Months
-77.97%
1 Year
-87.73%
3 Years
-
5 Years
-
10 Years
-

Name / TickerPriceChg.Chg.%
ECOR1.690.00000.00
AAPL210.610.26000.12
GOOG1 182.69-15.7600-1.32
MSFT137.26-1.1500-0.83
XOM69.03-0.4200-0.60
WFC44.68-0.5700-1.26
JNJ130.60-1.6500-1.25
FB183.81-2.3600-1.27
GE8.38-0.2900-3.34
JPM107.31-1.3800-1.27
Earnings HistoryEstimateReportedSurprise %
Q02 2019--0.41-
Q01 2019--0.47-
Q04 2018--0.52-
Q03 2018--0.45-
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2019 FY-1.3032.29Positive
12/2020 FY-1.0525.00Positive
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume90 923
Shares Outstanding (in ths.)29 594
Trades Count200
Dollar Volume71 920
Avg. Volume177 861
Avg. Weekly Volume145 264
Avg. Monthly Volume91 026
Avg. Quarterly Volume224 416
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
2 (50.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (50.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Buy
2.33
Moderate Buy
2.00
Strong Buy
1.50

electroCore Inc.

electroCore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. The company's product gammaCore is FDA-cleared for adjunctive use for the preventive treatment of cluster headache and for the acute treatment of pain associated with episodic cluster headache and migraine headache in adult patients.

CEO: Francis R. Amato

Teplephone: +1 888 903-2673

Address: 150 Allen Road, Basking Ridge 07920, NJ, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

67%33%

News